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Abstract
Molecular microbiology has revolutionized the landscape of microbiology and will continue to do so by providing new solutions for
microbe identiﬁcation and characterization. This applies also to the study of Helicobacter pylori where current genotypic (molecular)
methods are important complements or alternatives to phenotypic methods. Besides providing sensitivity and speciﬁcity and an
enhancement of the detection process, they also reduce much of the subjectivity inherent in the interpretation of morphological and
biological data. Another key advantage of molecular methods is that they allow the identiﬁcation of novel virulence factors of pathogenic
bacteria. For example, such gene products enable H. pylori to establish itself within the gastric environment and enhance its potential to
cause disease. Next-generation sequencing will open up new areas of research for those involved in the ﬁeld of Helicobacter research
and will also provide information that will help to develop novel treatment strategies and increase our understanding of the mechanisms
behind chronic inﬂammations in the gut. The analysis of data resulting from a large-scale sequencing project requires the use of bioinfor-
matics, including standard BLAST analysis, annotation or clustering, and assembly competence. However, the amount of data produced
by the next-generation sequencing platforms will require a bioinformatics capacity at the industrial scale, which may limit the availability
of such technologies. Consequently, building effective new approaches to data analysis must be given high priority.
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Technology Platforms
Growing demand in both the research and clinical markets
has fueled the development of more efﬁcient genomic
sequencing methods [1,2]. Such methods are already several
orders of magnitude more efﬁcient than the Sanger capillary-
array electrophoresis machines that were used in the human
genome project. Massively parallel DNA sequencing plat-
forms have not only reduced the cost of DNA sequencing,
but also have moved the technology from major genome
centres to individual investigators. The new platforms will
dramatically accelerate biological and biomedical research, by
enabling the comprehensive analysis of genomes to become
inexpensive, routine and widespread. Below, three commer-
cial systems are brieﬂy described (Table 1) and each of them
has the potential to contribute to our knowledge concerning
Helicobacter pylori.
Roche/454 FLX pyrosequencer
Multiple whole prokaryote genomes can easily be sequenced
using the 454 FLX system (Roche Diagnostics, Basel, Switzer-
land.) [3,4]. This high-throughput technology that sequences
in real time provides long reads (400 bp) that facilitate the
completion of near-ﬁnished draft sequences in a single instru-
ment run. Large-size genomic DNA samples are randomly
fragmented into small 300- to 800-bp fragments for shotgun
sequencing. Addition of adapters to the fragments creates a
library of DNA fragments, which is immobilized on DNA
capture beads, whereafter PCR ampliﬁcation takes place in
water-in-oil microreactors, resulting in millions of copies of
the template. Finally, the microreactor is broken and beads
ª2009 The Author
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2009.02962.x
carrying single-stranded DNA templates are individually
sequenced on a picotitre plate device. The generated
sequences are then assembled into a number of unordered
contigs using speciﬁc assembler software. Finally, a consensus
sequence is generated.
The sequencing depth achieved with 454 FLX titanium
sequencing systems ensures the accurate characterization of
microbial or bacterial diversity, the sensitive detection of
even rare mutations, and the rapid discovery of the disease-
causing agents [5]. Furthermore, this system for ultra-high-
throughput DNA sequencing is used for de novo sequencing
and resequencing of genomes, for metagenomics, and for tar-
geted sequencing of DNA regions of interest. The newest
version generates up to 400 million bases per 10-h instru-
ment run. The key advantage of this technology is read-
length (up to 400 bp, which is necessary in de novo assembly
and metagenomics). However, a major limitation is that no
prevention of multiple incorporations at a given cycle is pro-
vided, which leads to homopolymer errors.
The technology has enabled a number of peer-reviewed
studies in diverse research ﬁelds, such as cancer and infec-
tious diseases, drug discovery, marine biology, anthropology,
paleontology, and many more. The value of the FLX System
for bacterial sequencing applications is emphasized by a num-
ber of important studies, including a study of Mycobacterium
tuberculosis that resulted in the identiﬁcation of the ﬁrst
tuberculosis-speciﬁc drug candidate in 40 years [6]. FLX Sys-
tem pyrosequencing has so far been the method of choice
for sequencing of H. pylori and for exploring the human
stomach microbiota [7,8].
Illumina/Solexa genome analyzer
Illumina sequencing technology (Illumina Inc., San Diego, CA,
USA), or the Solexa platform, allows for the selection of any
single-nucleotide polymorphism or probe, enabling dense,
uniform coverage across the genome and the ability to target
any genomic region [9,10]. This platform is based on mas-
sively parallel sequencing of millions of fragments using
a reversible terminator-based sequencing chemistry. The
technology, together with a software application, allows a
scalable system that many consider cost-effective and accu-
rate. It relies on the attachment of randomly fragmented
genomic DNA to an optically transparent surface. Attached
DNA fragments are extended and subjected to bridge ampli-
ﬁcation to create an ultra-high-density sequencing ﬂow cell
with ‡50 million clusters, each containing approximately
1000 copies of the same template. These templates are
sequenced using a four-colour DNA sequencing-by-synthesis
technology that employs reversible terminators with remov-
able ﬂuorescent dyes. This approach ensures high accuracy
and true base-by-base sequencing, eliminating sequence
context-speciﬁc errors and enabling sequencing through
repetitive sequences. After completion of the ﬁrst read, the
templates can be regenerated in situ to enable a second
>36-bp read from the opposite end of the fragments. A
paired-end module directs the regeneration and ampliﬁcation
operations to prepare the templates for the second round of
sequencing. Once the original templates are cleaved and
removed, the reverse strands undergo sequencing-by-synthe-
sis. The second round of sequencing occurs at the opposite
end of the templates, generating >36 bp reads for a total of
>3 Gb of data, which is an obvious advantage when sequencing
large genomes. The short read-length (35 bp) is a limitation
but, compared with 454 FLX pyrosequencing, homopolymer
errors are less of an issue with this technology.
Applied Biosystems SOLiDTM system
Sequencing by ligation generates DNA by measuring the
serial ligation of an oligonucleotide. This technology is used
in the SOLiD system (Applied Biosystems, Foster City, CA,
USA) [11,12]. All ﬂuorescently labelled oligonucleotide
probes are present simultaneously and compete for incorpo-
ration. After each ligation, the ﬂuorescence signal is mea-
sured and then cleaved before another round of ligation
takes place. The SOLiD system is a massively parallel geno-
mic analysis platform that supports a wide range of applica-
tions. The ﬂexibility of two independent ﬂow cells allows
multiple experiments in a single run. The SOLiD system can
cost effectively complete large-scale sequencing and, with a
reference sequence for a microorganism, it is possible to
TABLE 1. Comparison of next-gen-
eration sequencing technologies
454 FLX Solexa SOLiD
Read length 250–400 bp 25–35 bp 25–35 bp
Reads 1 M 30 M 90 M
Data 400 Mb 3 Gb 30 Gb
Scale-up of number of reads + +++ +++
Future increase of read length ++ + +
Access to instruments +++ +++ +++






Advantages Long read length Easy to scale up Easy to scale up
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perform comparative sequencing or re-sequencing to charac-
terize the genetic diversity within the organism’s species or
between closely-related species. The throughput is greater
than 30 GB per run, although the read-length is limited to
35 bp.
Genome-wide Assessment of H. pylori:
Insight into the Helicobacter Supragenome
The next-generation DNA sequencing platforms will soon be
available in many research laboratories, which will allow
researchers interested in H. pylori evolution, pathogenicity,
colonization and other aspects to perform sequencing pro-
jects at the whole genome level. Comparative genomic analy-
ses of many H. pylori strains will, for example, provide
insights into the Helicobacter supragenome. Currently, we
have some knowledge about the genomic plasticity of the
H. pylori species; this genetic diversity calls attention to the
need for markers of human virulence phenotypes and high-
lights the potential difﬁculty associated with this task.
H. pylori strains are presently categorized according to cer-
tain proposed virulence-associated genes such as cagA and
other genes in the cagPAI group. Additional potential viru-
lence factors of H. pylori are so far unknown [13,14].
Only 10% of H. pylori infections are associated with severe
pathology, including chronic gastritis, peptic ulcer, gastric ade-
nocarcinoma and gastric mucosa-associated lymphoid tissue
(MALT) lymphoma. Evolution of the bacterial infection
towards malignancy only occurs in approximately 1% of the
infected population, emphasizing the importance of markers
that are able to discriminate between benign and pathogenic
infections at an early stage. Numerous studies have focused
on the identiﬁcation of H. pylori genes associated with patho-
genicity and such genes have served as virulence biomarkers.
The current biomarkers fail, however, to discriminate among
various H. pylori-related diseases and the importance of identi-
fying such biomarkers for a given patient is controversial [15].
Comparative analyses of the ﬁrst two Western H. pylori
genome sequences (J99 isolated from a peptic ulcer patient
[16] and 26695 [17] isolated from a patient with gastritis)
revealed a signiﬁcant macrodiversity (i.e. the presence or
absence of the genes) and microdiversity (polymorphisms)
[18]. The macrodiversity of H. pylori isolates was further
illustrated by the comparative genome analysis of 15 Cauca-
sian isolates, in a study that aimed to identify the core
H. pylori genome and the strain-speciﬁc genes [19]. This com-
parison allowed the fraction of strain-speciﬁc genes to be
extended from 6–7% (as determined by the comparison of
the ﬁrst two sequenced genomes) to 18–22%. More recently,
Gressmann et al. [20] conducted a large study of 56 H. pylori
and four Helicobacter acinonychis strains using whole genome
microarrays. By extrapolation, it was estimated that the core
H. pylori genome contains 1111 genes and that a weighted
average of 27% of the genome is variably present in different
isolates [20]. The whole genome array approach is limited to
published genes present on the array and does not provide
information about unknown genes in clinical isolates.
The next-generation sequencing platforms will avoid this
limitation. We will have the opportunity to compare the
genomes of a large number of isolates from speciﬁc gastro-
duodenal diseases aiming to obtain knowledge of H. pylori
genes uniquely associated with these diseases (i.e. more
strain-speciﬁc genes will be discovered). The data will extend
our knowledge of the H. pylori core genome and suprage-
nome (the collective genome of all H. pylori strains) and thus
simplify the identiﬁcation of strain-speciﬁc markers.
Another potential ﬁeld of application is to extend the mul-
tilocus sequence typing approach to whole genome sequenc-
ing of H. pylori in studies of human migration. Now that
H. pylori has become a marker of human prehistoric migra-
tion, whole genome sequencing of representative strains of
the bacteria will probably increase our understanding
of human expansion and help to determine when different
parts of the world were peopled [21].
A large amount of intraspecies genetic variation has been
observed for several bacteria. Analysis of 13 Haemophilus
inﬂuenzae genomes showed that only approximately 50% of
the genes were conserved among all strains [22]. This study
supports the distributed-genome hypothesis, which states
that the full complement of genes available to a given species
exists in a supragenome pool, comprising one that each
member of a population of naturally transformable bacterial
strains contributes to and draws from, resulting in a high
degree of genic diversity [23]. In another study, the genomes
of eight clinical Streptococcus pneumoniae isolates were
sequenced by 454 FLX pyrosequencing and combined with
sequences from nine additional publicly available S. pneumo-
niae strains [24]. A global comparative analysis of the genes
and genomes was performed and demonstrated a great
genetic diversity among the strains. This total of 17 genomes
contained orthologues shared among all strains (core genes),
orthologues shared only between subsets of two or more
strains (distributed genes), and genes unique to one strain.
Genes from all strains were grouped into orthologous clus-
ters and divided into the three categories.
The study by Hiller et al. [24] revealed that S. pneumoniae
has a supragenome much larger than the genome of any individ-
ual strain. A mathematical model was also used to calculate the
number of strains that needs to be sequenced to determine
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the S. pneumoniae supragenome. The calculated number of
strains required to identify 90% of the pneumococcal suprage-
nome was 142. Hiller et al. [24] concluded that the pneumo-
coccal diversity must lead to caution in the use of model
strains to test and develop vaccines and drugs because effective
targets in one strain may be missing in a signiﬁcant percentage
of the other strains. They speculated about the possibility that
these bacteria have evolved multiple and redundant mecha-
nisms to evade immunity and adapt to variations among hosts
and their commensal microbiota. A similar evolvement can be
attributed to H. pylori and, by using the next-generation
sequencing platforms, we will probably be aware of this situa-
tion in the context of vaccine and drug development for
H. pylori infection.
A similar approach to gaining insight into the H. pylori gen-
ome is a natural step for people in this ﬁeld of research.
One possibility is to use the 454 FLX pyrosequencing plat-
form that allows for long reads (up to 400 bp) and a
sequencing depth that ensures accurate whole genome
sequencing of up to 25 H. pylori isolates per instrument run.
Various H. pylori-associated diseases such as gastric MALT
lymphoma, atrophic gastritis, gastric adenocarcinoma and
duodenal ulcers should be included in these studies, together
with control strains from asymptomatic individuals with
chronic gastritis. By using sample-speciﬁc adaptors ligated
onto each DNA fragment in a library sample, the GS FLX
analysis software will recognize each adaptor, allowing for
automated sorting and analysis of sample-speciﬁc reads.
We have used a similar approach to investigate the micro-
bial contents in the human throat, stomach and in faecal
samples [8]. DNA was extracted from each sample and the
16S rRNA gene contents were ampliﬁed by PCR using uni-
versal 16S primers. By using short sample-speciﬁc sequence
tags, incorporated during the initial 16S PCR reactions, each
sequence obtained on the picotitre plate was traced back to
its original sample (i.e. a variant of the adaptor ligation
approach above). We found an outstanding adaptation of
H. pylori to the gastric environment in stomach samples that
were positive for H. pylori. This bacterium dominated totally
(accounting for >93% of the reads) in the diverse microbial
communities of the investigated stomachs. The 454 FLX
pyrosequencing platform allowed us to explore the gut mic-
robiota with a sequencing depth that ensures an accurate
characterization. Similar approaches for analyses of the gut
microbiota have been reported recently [25–27].
By using gaskets, which physically divide the picotitre plate
device into two smaller regions, 12 H. pylori DNA libraries can
be sequenced on each side (450–650 000 reads per region).
Based on the size of the H. pylori genome (1.6 Mb), one can
estimate that this approach will generate an eight- to ten-fold
greater coverage. By using mathematical models similar to
those used for S. pneumoniae, it should be possible to estimate
the number of whole genome-sequenced H. pylori strains
required to deﬁne the supragenome of the bacteria [24]. The
sequencing data from 25 H. pylori strains and the four previ-
ously published genomes (J99, 26695, HPAG1 and G27)
[7,16,17,28] can then be compared to identify common, vari-
able and strain-speciﬁc genes. To reach statistical signiﬁcance,
a power calculation is required, and such studies should only
be performed on epidemiologically well-designed material rep-
resenting true cases and controls [29]. Thus, strain speciﬁc
genes can then be investigated to identify potentially novel vir-
ulence genes. The meta-genome data from such studies will
also serve as a template for the design of microarrays, which
will facilitate comparative genome hybridization experiments
of a signiﬁcantly larger number of strains. The expected
outcome of such studies includes the identiﬁcation of novel
biomarkers that could potentially be used to classify H. pylori
infections in a clinical setting.
Identifying Compensatory Mutations in
Resistant H. pylori
Another study approach for next-generation sequencing
comprises comparative genomics in H. pylori strains before
and after treatment failures (i.e. when H. pylori develops
resistance to the drug). We know that the correlation
between the volume of drugs used and resistance develop-
ment, together with the observation that resistance determi-
nants often confer a ﬁtness cost, has led to the question: is
the development of antibiotic resistance reversible?
In an environment containing antibiotics, possession of the
corresponding resistance gene confers a beneﬁt to the
organism. However, in a drug-free environment, resistant
genotypes might have a lower ﬁtness (i.e. reproductive abil-
ity) than their sensitive counterparts [30]. The reproductive
ability is affected by several parameters, such as the relative
rates at which susceptible and resistant bacteria grow in
their hosts and in the environment, and how this affects
clearance and transmission rates.
The ﬁtness cost that chromosomal resistance mutations
and plasmids often confer to the cells makes them less com-
petitive than susceptible strains in an antibiotic-free environ-
ment. Counteracting this is the selection for a decreased
cost of resistance. This can be accomplished by reversion of
the resistance mutation or acquisition of a second-site com-
pensatory mutation, restoring ﬁtness close to or equal to
the susceptible strains. One can conclude from several in vitro
investigations that, under most conditions, compensation
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rather then reversion is a more frequent event. This is
because the mutational target for compensation is larger
than for reversion.
From the perspective of reversibility of antibiotic resis-
tance, compensation represents a substantial problem. This
is because compensatory mutations most often do not
reduce resistance levels or affect the resistance mechanism
when restoring ﬁtness. This inﬂuences the time required to
reduce the population of resistant bacteria, which is inversely
proportional to the cost of resistance. If the ﬁtness cost of a
resistance mutation is reduced to 1% by compensatory
events, it will take 20 times longer to eliminate the compen-
sated population (by the take-over from a susceptible clone)
than it would have taken for the uncompensated resistant
population with 20% lower ﬁtness.
To assess the probability of reversibility of antibiotic resis-
tance, it is vital to determine the ﬁtness effect of resistance
and compensatory mechanism in clinical isolates [31]. The
problem with conducting studies in clinical isolates is the lack
of functioning genetic tools (i.e. phages, transposomes and
plasmids), if they exist at all for the organism in question,
making these types of investigations basically difﬁcult to con-
duct. However, one way of overcoming the problem is to
apply a whole genome sequencing approach, with high-
throughput sequencing techniques (454 FLX pyrosequencing,
Solexa or SOLiD), to identify potential resistance and com-
pensatory mechanisms.
The extensive strain material existing for H. pylori, from
both before and after (failed) antibiotic treatment in the same
patient, in combination with its chronic and clonal colonization
proﬁle, makes H. pylori an ideal candidate for assessing the ﬁt-
ness cost of resistance and for the identiﬁcation of potential
compensatory mechanisms. These types of studies have to
forego any broadscale reversibility intervention for a speciﬁc
antibiotic, which is also a fundamental requirement for assess-
ing the risk of a worldwide eradication policy for H. pylori.
We have successfully sequenced four H. pylori isolates
obtained from two patients before and after treatment using
the 454 FLX pyrosequencer. The resistant isolates obtained
after treatment showed different ﬁtness in a mouse model
[31] and, by employing the 454 FLX approach, we have iden-
tiﬁed a number of potential targets for ﬁtness compensation
and narrowed these down to a few targets (manuscript in
preparation).
Considerations and Challenges
The next-generation DNA sequencing platforms will, without
doubt, be applied to a variety of goals within the H. pylori
research ﬁeld. A number of reference genomes have been
available for H. pylori for several years and the next possibil-
ity will be to resequence, perhaps not all the H. pylori
genomes, but the regions of the genome to which a disease
phenotype has been mapped. One example is to understand
the adaptations of H. pylori to a persistent infection. We
generated and ﬁnished the whole genome sequence for
strain HPAG1 [7] using traditional Sanger sequencing with a
ABI 3730xl capillary sequencer and, independently, using 454
FLX pyrosequencing. With both technologies, we identiﬁed
43 genes that were not detectable in the previously
sequenced Hp 26695 or J99 strains from patients with acid-
peptic disease, and 31 genes whose open reading frames
were divided due to frameshifts in this, but not in the other,
strains; a number of these latter genes were acid-regulated
in the 26695 or J99 isolates. Another aim is to obtain a
whole genome view of H. pylori evolution as individual human
hosts progress from a normal gastric mucosa to precancer
lesions (i.e. chronic atrophic gastritis). We will use the 454
FLX pyrosequencing platform to obtain deep draft whole
genome sequences of H. pylori isolates obtained from serial
endoscopies of individuals enrolled in a population-based
endoscopy study [32]. H. pylori-infected individuals who
progressed from having a normal gastric mucosa to atrophic
gastritis during the 4-year interval between endoscopic
examinations will be compared to sex -and age-matched con-
trol patients who did not progress (whose mucosa remained
histologically normal). The relatively small size of the H. pylori
genome will make 454 FLX pyrosequencing of multiple
H. pylori isolates technically and economically feasible.
In addition to bacterial sequencing and comparative
genomics, the next-generation sequencing platforms will
provide us with a tool to study transcriptional expression
and small RNA proﬁles of H. pylori. Such studies have been
performed in Salmonella, where deep sequencing analysis of
small noncoding RNA revealed a number of novel small
RNAs associated with a post-transcriptional regulator, Hfq,
that controls almost 20% of all salmonella genes [33].
A list of applications that will raise new challenges for
experimental design and interpretation of results has recently
been described [1,2,5]. However, the large amount of data
generated by these instruments should lead to biologically
meaningful insights and, hopefully, to clinical strategies and
novel treatment options for H. pylori-infected individuals.
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